サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1291413

抗肥満薬市場：世界の産業動向、シェア、規模、成長機会、2023-2028年予測

Anti-Obesity Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗肥満薬市場：世界の産業動向、シェア、規模、成長機会、2023-2028年予測
出版日: 2023年05月29日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場概要：

世界の抗肥満薬市場規模は、2022年に20億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に11.7%の成長率（CAGR）を示し、2028年までに40億米ドルに達すると予測しています。

抗肥満薬は、体重の減少やコントロールを目的としており、一般的には病的な肥満の場合にのみ医療用医薬品として処方されます。特にお菓子や脂肪分、塩分、高カロリーの食品に対する欲求を抑え、強迫的な摂食を抑制する効果があります。また、血圧、有害な脂質レベル、ウエスト周囲径、糖度、非アルコール性脂肪肝疾患（NAFLD）をコントロールし、主要な心血管疾患（CVD）のリスクや糖尿病性腎臓病の進行を最小限に抑えるなど、独自の健康効果をもたらすことができます。

抗肥満薬の市場動向：

抗肥満薬の最近の進歩により、臨床的に有意な体重減少を達成する可能性が出てきました。これは、座りがちな生活習慣による肥満の蔓延と相まって、市場の見通しを良好にする重要な要因の一つとなっています。さらに、肥満は2型糖尿病（T2D）、心血管疾患（CVD）、食道、結腸・直腸、肝臓、胆嚢、膵臓、腎臓のがんの発症リスクを高めると言われています。また、数多くの精神疾患、神経疾患、肺疾患、消化器疾患、腎疾患、筋骨格系疾患、内分泌疾患を引き起こす可能性があります。さらに、睡眠不足、概日リズムの乱れ、慢性的なストレス、抗てんかん薬や向精神薬の使用増加などが、体重増加をさらに誘発する可能性があります。食欲や食への欲求を調整する抗肥満薬（AOM）の承認件数が増加していることと相まって、市場の成長に拍車をかけています。これとは別に、減量は個人の生活の質、運動能力、日常生活機能、心理的幸福を向上させるのに役立つ。これに加えて、健康意識の高まり、製薬業界の繁栄、体重超過と密接に関連する疾患の管理への注目の高まりが、市場の成長を刺激すると予想されます。

本レポートで回答した主な質問

  • 2022年の世界の抗肥満薬市場規模は？
  • 2023年～2028年の世界の抗肥満薬市場の予想成長率はどのくらいか？
  • 世界の抗肥満薬市場を牽引する主要因は何か？
  • COVID-19が世界の抗肥満薬市場に与えた影響とは？
  • 薬剤クラスに基づく世界の抗肥満薬市場の内訳は？
  • 薬剤タイプに基づく抗肥満薬の世界市場の内訳は？
  • 流通チャネルに基づく抗肥満薬の世界市場の内訳は？
  • 抗肥満薬の世界市場における主要地域はどこか？
  • 世界の抗肥満薬市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要な産業動向

第5章 抗肥満薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 薬剤クラス別市場内訳

  • 末梢作動性薬
    • 市場動向
    • 市場予測
  • 中枢作用薬
    • 市場動向
    • 市場予測

第7章 薬剤タイプ別市場内訳

  • 医療用医薬品
    • 市場動向
    • 市場予測
  • OTC医薬品
    • 市場動向
    • 市場予測

第8章 流通チャネル別市場内訳

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第9章 地域別市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋地域
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 国別市場内訳
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Gelesis
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Norgine B.V.
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals Inc.
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
図表

List of Figures

  • Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2022
  • Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
  • Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
  • Table 7: Global: Anti-Obesity Drugs Market: Key Players
目次
Product Code: SR112023A5544

Market Overview:

The global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2028, exhibiting a growth rate (CAGR) of 11.7% during 2023-2028.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, drug type and distribution channel.

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

  • Prescription Drugs
  • OTC Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report:

  • What was the size of the global anti-obesity drugs market in 2022?
  • What is the expected growth rate of the global anti-obesity drugs market during 2023-2028?
  • What are the key factors driving the global anti-obesity drugs market?
  • What has been the impact of COVID-19 on the global anti-obesity drugs market?
  • What is the breakup of the global anti-obesity drugs market based on the drug class?
  • What is the breakup of the global anti-obesity drugs market based on the drug type?
  • What is the breakup of the global anti-obesity drugs market based on distribution channel?
  • What are the key regions in the global anti-obesity drugs market?
  • Who are the key players/companies in the global anti-obesity drugs market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Anti-Obesity Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Class

  • 6.1  Peripherally Acting Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Centrally Acting Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7   Market Breakup by Drug Type

  • 7.1  Prescription Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  OTC Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8   Market Breakup by Distribution Channel

  • 8.1  Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10  SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Boehringer Ingelheim International GmbH
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2  Currax Pharmaceuticals LLC
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3  Gelesis
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4  GlaxoSmithKline plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5  Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6  Norgine B.V.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7  Novo Nordisk A/S 
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8  Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9  Rhythm Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10  SHIONOGI & Co. Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11  Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12  Vivus LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio